|
US5137874A
(en)
*
|
1985-07-29 |
1992-08-11 |
American Cyanamid Co. |
Partially coated C10 -C20 fatty acid salts of peptides having molecular weights up to about 5,000
|
|
IL79134A
(en)
*
|
1985-07-29 |
1991-06-10 |
American Cyanamid Co |
Continuous release peptide implants for parenteral administration
|
|
US4892742A
(en)
*
|
1985-11-18 |
1990-01-09 |
Hoffmann-La Roche Inc. |
Controlled release compositions with zero order release
|
|
CA1257199A
(en)
*
|
1986-05-20 |
1989-07-11 |
Paul Y. Wang |
Preparation containing bioactive macromolecular substance for multi-months release in vivo
|
|
AU601736B2
(en)
*
|
1986-05-23 |
1990-09-20 |
Sanofi Sante Nutrition Animale Sa |
Coated veterinary implants
|
|
WO1989005138A1
(en)
*
|
1987-12-08 |
1989-06-15 |
Mark Chasin |
Method of forming bioerodible implants for improved controlled drug release
|
|
JP2590358B2
(ja)
*
|
1988-03-01 |
1997-03-12 |
正雄 五十嵐 |
子宮内膜症治療用の子宮内又は膣内投与製剤
|
|
CA2071867A1
(en)
*
|
1989-11-06 |
1991-05-07 |
Edith Mathiowitz |
Method for producing protein microspheres
|
|
CA2046830C
(en)
*
|
1990-07-19 |
1999-12-14 |
Patrick P. Deluca |
Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
|
|
EP0723402B1
(en)
|
1993-08-30 |
2010-08-18 |
Baylor College Of Medicine |
Senescent cell-derived inhibitors of dna synthesis
|
|
US5599535A
(en)
*
|
1995-06-07 |
1997-02-04 |
Regents Of The University Of California |
Methods for the cyto-protection of the trabecular meshwork
|
|
US5674888A
(en)
*
|
1995-06-07 |
1997-10-07 |
University Of California |
Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
|
|
US7005505B1
(en)
|
1995-08-25 |
2006-02-28 |
Genentech, Inc. |
Variants of vascular endothelial cell growth factor
|
|
US6020473A
(en)
*
|
1995-08-25 |
2000-02-01 |
Genentech, Inc. |
Nucleic acids encoding variants of vascular endothelial cell growth factor
|
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
|
JP3860841B2
(ja)
|
1996-08-30 |
2006-12-20 |
ペプテック リミテッド |
持続性ペプチド放出製剤
|
|
US7138511B1
(en)
|
1997-01-28 |
2006-11-21 |
The Regents Of The University Of California |
Nucleic acids, kits and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
|
|
US6171788B1
(en)
|
1997-01-28 |
2001-01-09 |
The Regents Of The University Of California |
Methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
|
|
US6475724B1
(en)
|
1997-01-28 |
2002-11-05 |
The Regents Of The University Of California |
Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
|
|
EP2050762A3
(en)
|
1998-03-10 |
2009-07-08 |
Genentech, Inc. |
Human cornichon-like protein and nucleic acids encoding it
|
|
US7078382B1
(en)
|
1999-11-02 |
2006-07-18 |
Genentech, Inc. |
Modulation of eNOS activity and therapeutic uses thereof
|
|
US20040224000A1
(en)
*
|
2003-05-05 |
2004-11-11 |
Romano Deghenghi |
Implants for non-radioactive brachytherapy of hormonal-insensitive cancers
|
|
EP2612852A1
(en)
|
2004-05-23 |
2013-07-10 |
Gerard M. Housey |
Theramutein modulators
|
|
US8431110B2
(en)
|
2005-05-23 |
2013-04-30 |
Hmi Medical Innovations, Llc. |
Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
|
|
RU2518295C2
(ru)
|
2005-06-21 |
2014-06-10 |
Ксома Текнолоджи Лтд. |
IL-1бета-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ФРАГМЕНТЫ
|
|
ATE480267T1
(de)
*
|
2006-01-05 |
2010-09-15 |
Med Inst Inc |
Zein-beschichtete medizinische vorrichtung
|
|
EP2094306A2
(en)
|
2006-12-20 |
2009-09-02 |
XOMA Technology Ltd. |
Treatment of il-1-beta related diseases
|
|
EP2190448B1
(en)
|
2007-06-22 |
2016-04-20 |
Children's Medical Center Corporation |
Methods and uses thereof of a fragment of saposin a
|
|
EP2214747A2
(en)
|
2007-11-20 |
2010-08-11 |
Cook Incorporated |
Controlled drug delivery using a zein layer modified with levulinic acid
|
|
US8637029B2
(en)
|
2007-12-20 |
2014-01-28 |
Xoma Technology Ltd. |
Methods for the treatment of gout
|
|
WO2010144797A2
(en)
|
2009-06-12 |
2010-12-16 |
Vaccine Technologies, Incorporated |
Influenza vaccines with enhanced immunogenicity and uses thereof
|
|
CN101669899B
(zh)
*
|
2009-09-29 |
2011-02-02 |
河北科技大学 |
玉米蛋白为主要骨架材料或基质的缓释埋植剂及其用途
|
|
AU2010339794B2
(en)
|
2009-12-17 |
2016-09-22 |
Children's Medical Center Corporation |
Saposin-A derived peptides and uses thereof
|
|
EP2550289A4
(en)
|
2010-03-12 |
2013-11-27 |
Childrens Medical Center |
NEW IMMUNOGENES AND METHODS FOR IDENTIFICATION AND SCREENING THEREOF
|
|
CN101843577A
(zh)
*
|
2010-04-08 |
2010-09-29 |
安徽中医学院 |
以玉米醇溶蛋白为骨架材料的包衣植入剂及制备方法
|
|
CN104203275A
(zh)
|
2010-06-09 |
2014-12-10 |
疫苗技术股份有限公司 |
用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
|
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
|
WO2012155053A1
(en)
|
2011-05-11 |
2012-11-15 |
Children's Medical Center Corporation |
Modified biotin-binding protein, fusion proteins thereof and applications
|
|
WO2013028541A1
(en)
|
2011-08-19 |
2013-02-28 |
Children's Medical Center Corporation |
Vegf-binding protein for blockade of angiogenesis
|
|
CN104144946A
(zh)
|
2011-12-19 |
2014-11-12 |
爱克索马美国有限责任公司 |
治疗痤疮的方法
|
|
EP3560509B1
(en)
|
2011-12-22 |
2024-01-31 |
Children's Medical Center Corporation |
Saposin-a derived peptides and uses thereof
|
|
JP6684490B2
(ja)
|
2012-01-09 |
2020-04-22 |
ザ・スクリップス・リサーチ・インスティテュート |
超長相補性決定領域及びその使用
|
|
JP2015509091A
(ja)
|
2012-01-09 |
2015-03-26 |
ザ スクリプス リサーチ インスティテュート |
ヒト化抗体
|
|
AU2014214844B2
(en)
|
2013-02-07 |
2017-12-14 |
Children's Medical Center Corporation |
Protein antigens that provide protection against pneumococcal colonization and/or disease
|
|
WO2015017146A2
(en)
|
2013-07-18 |
2015-02-05 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
|
AU2014290361B2
(en)
|
2013-07-18 |
2019-04-18 |
Taurus Biosciences, Llc |
Humanized antibodies with ultralong complementarity determining regions
|
|
EP3043824B1
(en)
|
2013-09-13 |
2022-07-06 |
The Scripps Research Institute |
Modified therapeutic agents and compositions thereof
|
|
JP6734774B2
(ja)
|
2013-10-15 |
2020-08-05 |
ザ スクリプス リサーチ インスティテュート |
ペプチドキメラ抗原受容体ｔ細胞スイッチおよびその使用
|
|
US20150238631A1
(en)
|
2013-10-15 |
2015-08-27 |
The California Institute For Biomedical Research |
Chimeric antigen receptor t cell switches and uses thereof
|
|
US10039809B2
(en)
|
2013-12-18 |
2018-08-07 |
The California Institute For Biomedical Research |
Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
|
|
EP2977758A1
(en)
|
2014-07-24 |
2016-01-27 |
Université De Nice Sophia Antipolis |
Methods and kits for monitoring membranous nephropathy
|
|
WO2016154621A1
(en)
|
2015-03-26 |
2016-09-29 |
The California Institute For Biomedical Research |
SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
|
|
EP3283113A4
(en)
|
2015-04-15 |
2018-12-05 |
The California Institute for Biomedical Research |
Optimized pne-based chimeric receptor t cell switches and uses thereof
|
|
WO2016205488A1
(en)
|
2015-06-17 |
2016-12-22 |
The California Institute For Biomedical Research |
Modified therapeutic agents and compositions thereof
|
|
WO2018075807A1
(en)
|
2016-10-19 |
2018-04-26 |
California Institute For Biomedical Research |
Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
|
|
MX2022001732A
(es)
|
2019-08-12 |
2022-05-06 |
Purinomia Biotech Inc |
Metodos y composiciones para promover y potenciar la respuesta inmunitaria mediada por linfocitos t dirigida a la adcc de las celulas con expresion de cd39.
|
|
AU2020371784A1
(en)
|
2019-10-24 |
2022-06-02 |
Minotaur Therapeutics, Inc. |
Chimeric cytokine modified antibodies and methods of use thereof
|
|
US20250197525A1
(en)
|
2021-04-28 |
2025-06-19 |
Minotaur Therapeutics, Inc. |
Humanized chimeric bovine antibodies and methods of use
|
|
WO2023212483A1
(en)
|
2022-04-29 |
2023-11-02 |
Purinomia Biotech, Inc. |
Methods and compositions for treating eosinophil driven diseases and disorders
|